Compare Abeona Therapeutics Inc (ABEO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Merck & Co., Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Merck & Co., Inc. trades at $126.54 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 852.5× Abeona Therapeutics Inc's market cap, and Merck & Co., Inc. pays a 2.64% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MRK | |
|---|---|---|
Market Cap | $373.32M | $318.26B |
Sector | Health | Health |
52-Week High | $7.23 | $129.52 |
52-Week Low | $4.17 | $77.60 |
Enterprise Value | $228.22M | $361.68B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Merck (MRK) trades at $126.61, down slightly by 0.13% today, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported solid earnings beats in recent quarters, with Q1 2026 loss narrower than expected, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The stock offers upside to the consensus price target of $139.33, driven by earnings momentum and expansion in high-margin drugs, but faces risks from patent expirations, regulatory scrutiny, and integration challenges from acquisitions. Investors should weigh the strong analyst buy rating (67.57%) against potential volatility from macroeconomic and industry-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
